FDA approves Zykadia for late-stage lung cancer

The U.S. Food and Drug Administration today granted accelerated approval to Zykadia (ceritinib) for patients with a certain type of late-stage (metastatic) non-small cell lung cancer (NSCLC).

Home | Copyright 2008-2024 FoodandDrugRecall.org